Pharmacodynamics of Overactive Bladder Drugs: Shifting the Curve

Current Bladder Dysfunction Reports

Volumn 6, Issue 1, 2011, Pages 51-63

  Staskin, David R ^a   Chawla, Rachna K ^b   Oefelein, Michael G ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Adverse effects; Bladder; Detrusor muscle; Dose response; Muscarinic receptor antagonists; OAB; Overactive bladder; Pharmacodynamics

Indexed keywords

ACETYLCHOLINE; ADENYLATE CYCLASE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; DARIFENACIN; EPHEDRINE; FESOTERODINE; FINASTERIDE; IMIPRAMINE; MATRIX METALLOPROTEINASE INHIBITOR; MIDODRINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; OXYBUTYNIN; PHENOXYBENZAMINE; PHOSPHOLIPASE C; PROTEIN KINASE C; SOLIFENACIN; SORAFENIB; SUNITINIB; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VANILLOID RECEPTOR;

ALZHEIMER DISEASE; ANXIETY; ASTHENIA; BLADDER CANCER; BLURRED VISION; CELL ADHESION; CELL INTERACTION; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEPRESSION; DETRUSOR MUSCLE; DIZZINESS; DOSE RESPONSE; DRUG RECEPTOR BINDING; DRY EYE; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HALLUCINATION; HEADACHE; HUMAN; INSOMNIA; INTRACELLULAR SIGNALING; KIDNEY CANCER; LIGAND BINDING; LIVER METABOLISM; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NEUROPHYSIOLOGY; OVERACTIVE BLADDER; PROSTATE HYPERTROPHY; PSYCHOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMNOLENCE; STOMACH MOTILITY; STRESS INCONTINENCE; UPPER ABDOMINAL PAIN; URINARY TRACT INFECTION; UROTHELIUM; XEROSTOMIA;

EID: 84873304442     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-010-0080-5     Document Type: Review

References (72)

1. Buxton IL (ed.): Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: The McGraw-Hill Companies; 2006: 3-27.
2. Cairo CW, Simon JB, Golan DE: Drug-receptor interactions. In Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Second Edition. Edited by Golan DE, Tashjian Jr AH, Armstrong EJ, Armstrong AW. Baltimore: Lippincott Williams & Wilkins; 2008: 3-18.
3. Staskin DR, Traub S: Pharmacokinetics of overactive bladder drugs: getting ahead of the curve. Curr Bladder Dysfunct Rep 2009, 4: 34-13.
4. Rose HS, Golan DE: Pharmacodynamics. In Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Second Edition. Edited by Golan DE, Tashjian Jr AH, Armstrong EJ, Armstrong AW. Baltimore: Lippincott Williams & Wilkins; 2008: 19-29.
5. Mansfield KJ, Chandran JJ, Vaux KJ, et al.: Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther 2009, 328: 893-899.
6. Abrams P, Andersson KE, Buccafusco JJ, et al.: Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006, 148: 565-578.
7. Rovner ES: Trospium chloride in the management of overactive bladder. Drugs 2004, 64: 2433-2446.
8. Apostolidis A, Dasgupta P, Denys P, et al.: Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 2009, 55: 100-119.
9. Caulfield MP, Birdsall NJ: International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998, 50: 279-290.
10. Andersson KE, Yoshida M: Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 2003, 43: 1-5.
11. Chess-Williams R, Chapple CR, Yamanishi T, et al.: The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001, 21: 243-248.
12. Nilvebrant L, Andersson KE, Gillberg PG, et al.: Tolterodine-a new bladder-selective antimuscarinic agent. Eur J Pharmacol 1997, 327: 195-207.
13. Hegde SS, Choppin A, Bonhaus D, et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997, 120: 1409-1418.
14. 2-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol 2000, 131: 1482-1488.
15. Kotlikoff MI, Dhulipala P, Wang YX: M2 signaling in smooth muscle cells. Life Sci 1999, 64: 437-442.
16. Chapple C: New once-daily formulation for trospium in overactive bladder. Int J Clin Pract 2010, 64: 1535-1540.
17. Daly DM, Chess-Williams R, Chapple C, Grundy D: The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol 2010, 58: 22-28.
18. Chuang YC, Thomas CA, Tyagi S, et al.: Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19: 1353-1357.
19. Kim Y, Yoshimura N, Masuda H, et al.: Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2006, 97: 400-403.
20. Frohlich G, Burmeister S, Wiedemann A, Bulitta M: [Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test]. Arzneimittelforschung 1998, 48: 486-491.
21. Allergan, Inc.: Sanctura (trospium chloride). Prescribing information. 2009.
22. Staskin DR: Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006, 33: 465-473, viii.
23. Staskin DR, MacDiarmid SA: Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 2006, 119: 9-15.
24. Harvey RD, Belevych AE: Muscarinic regulation of cardiac ion channels. Br J Pharmacol 2003, 139: 1074-1084.
25. Schneider T, Fetscher C, Krege S, Michel MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 2004, 309: 1148-1153.
26. Hegde SS: Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006, 147 Suppl 2: S80-S87.
27. Chapple CR, Khullar V, Gabriel Z, et al.: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54: 543-562.
28. Armstrong SR, Briones S, Horger B, et al.: Pharmacological analysis of the interaction of antimuscarinic drugs at M(2) and M(3) muscarinic receptors in vivo using the pithed rat assay. Naunyn Schmiedebergs Arch Pharmacol 2008, 376: 341-349.
29. Heading CE: YM-905 (Yamanouchi Pharmaceutical Ltd). Curr Opin CPNS Investig Drugs 2000, 2: 321-325.
30. de Groat WC: The urothelium in overactive bladder: passive bystander or active participant? Urology 2004, 64: 7-11.
31. Coelho A, Cruz F, Cruz CD, Avelino A: Effect of botulinum toxin type A on intramural parasympathetic ganglia of the guinea-pig bladder. J Urol 2010, 183: e76.
32. Olshansky B, Foote J, Arguinzoniz M, et al.: The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB) [abstract no. 124]. Presented at the 36th Annual Meeting of the International Continence Society (ICS). Christchurch, New Zealand; 2006.
33. Kay GG, Ebinger U: Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 2008, 62: 1792-1800.
34. Novartis: Enablex (darifenacin) extended release tablets. Prescribing information. 2008.
35. Staskin D, Kay G, Tannenbaum C, et al.: Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010, 64: 1294-1300.
36. Malhotra B, Wood N, Sachse R, Gandelman K: Lipophilicity of 5-hydroxymethyl tolterodine, the active metabolite of fesoterodine. Presented at the 4th International Consultation on Incontinence. Paris, France; 2008.
37. Andersson KE, Chapple CR, Cardozo L, et al.: Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009, 19: 380-394.
38. Hegde SS, Eglen RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999, 64: 419-428.
39. 3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366: 97-103.
40. Waldeck K, Larsson B, Andersson KE: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997, 157: 1093-1097.
41. Klausner AP, Steers WD: Antimuscarinics for the treatment of overactive bladder: a review of central nervous system effects. Curr Urol Rep 2007, 8: 441-447.
42. Kay G, Malhotra B, Michel MC: Assessment of central nervous system access of a new antimuscarinic drug, fesoterodine [abstract]. Presented at the American Urological Association Annual Meeting (AUA). Chicago, IL; April 25-30, 2009.
43. Wiedemann PA: Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same? A comparative review of data pertaining to pharmacological and physiological aspects. Eur J Ger 2007, 9: S29-42.
44. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41: 636-644.
45. Geyer J, Gavrilova O, Petzinger E: The role of p-glycoprotein in limiting brain penetration of the peripherally acting anticholinergic overactive bladder drug trospium chloride. Drug Metab Dispos 2009, 37: 1371-1374.
46. Pak RW, Petrou SP, Staskin DR: Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003, 4: 436-440.
47. Bernard S, Neville KA, Nguyen AT, Flockhart DA: Interethnic differences in genetic polymorphisms of CYP2D6 in the U. S. population: clinical implications. Oncologist 2006, 11: 126-135.
48. Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008, 46: 556-563.
49. Astellas Pharma US, Inc: VESIcare (solifenacin succinate) tablets. Prescribing information. 2008.
50. Ortho-McNeil-Janssen Pharmaceuticals Inc: Ditropan XL (oxybutynin chloride) extended release tablets. Prescribing information. 2009.
51. Pfizer & Upjohn Company: Detrol LA (tolterodine tartrate) extended release capsules. Prescribing information. 2008.
52. Pfizer Inc: Toviaz (fesoterodine fumarate) extended release tablets. Prescribing information. 2008.
53. DeMaagd G, Geibig JD: An overview of overactive bladder and its pharmacological management with a focus on anticholinergic drugs. Pharm Ther 2006, 31: 462-474.
54. Sandage B, Sabounjian L, Shipley J, et al.: Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol 2006, 46: 776-784.
55. Isik AT, Celik T, Bozoglu E, Doruk H: Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging 2009, 13: 672-676.
56. Guay DR: Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 1999, 19: 267-280.
57. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006, 45: 325-350.
58. Zipser BD, Johanson CE, Gonzalez L, et al.: Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007, 28: 977-986.
59. Kermode AG, Thompson AJ, Tofts P, et al.: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990, 113 (Pt 5): 1477-1489.
60. Beam TR, Jr., Allen JC: Blood, brain, and cerebrospinal fluid concentrations of several antibiotics in rabbits with intact and inflamed meninges. Antimicrob Agents Chemother 1977, 12: 710-716.
61. Starr JM, Wardlaw J, Ferguson K, et al.: Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2003, 74: 70-76.
62. Chancellor MB, Oefelein MG, Vasavada S: Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release. Neurourol Urodyn 2010, 29: 551-554.
63. Taniguchi CM, Armstrong SR, Green LC, et al.: Drug toxicity. In Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy, Second Edition. Edited by Golan DE, Tashjian AH, Armstrong EJ, Armstrong AW. Baltimore, MD: Lippincott Williams & Wilkins; 2008: 63-74.
64. Cruz-Orengo L, Dhaka A, Heuermann RJ, et al.: Cutaneous nociception evoked by 15-delta PGJ2 via activation of ion channel TRPA1. Mol Pain 2008, 4: 30.
65. Soontrapa S, Ruksakul W, Nonthasood B, Tappayuthpijarn P: The efficacy of Thai capsaicin in management of overactive bladder and hypersensitive bladder. J Med Assoc Thai 2003, 86: 861-867.
66. Alhasso A, Glazener CM, Pickard R, N'Dow J: Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005: CD001842.
67. Baker CH, Kedar D, McCarty MF, et al.: Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002, 161: 929-938.
68. Sudduth SL, Koronkowski MJ: Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 1993, 13: 309-325; discussion 325-309.
69. Tucker GC: Integrins: molecular targets in cancer therapy. Curr Oncol Rep 2006, 8: 96-103.
70. Lein M, Jung K, Ortel B, et al.: The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 2002, 21: 2089-2096.
71. Ney P, Pandita RK, Newgreen DT, et al.: Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008, 101: 1036-1042.
72. Napier C, Gupta P: Darifenacin is selective for the human recombinant M2 receptor subtype [abstract 445]. Presented at the Annual Meeting of the International Continence Society (ICS). Heidelburg, Germany; 2002.